Arrêt de la commercialisation des fils d’iridium 192 en France : proposition du groupe de curiethérapie de la Société française de radiothérapie oncologique

Abstract : In 2014, the production of iridium 192 wires in France ended. Thus brachytherapy departments had to move to high-dose rate and pulsed-dose rate afterloading techniques. Most of them had already made this migration for some indications, based on the habits and investments. The brachytherapy group organised meetings and opened discussions to share the clinical knowledge and answer to the questions raised by this migration. This made it possible to resolve and describe quite all the clinical and technical cases of brachytherapy. The development of high technology included the use of 3D dosimetry and optimisation of dose distribution and fractionation. The teaching policy of new technologies contributes to the improvement of treatment quality. Last but not least, a better reimbursement of brachytherapy is necessary and currently negotiated.
Document type :
Journal articles
Complete list of metadatas

https://hal.univ-lorraine.fr/hal-01801809
Contributor : Apemac Ul <>
Submitted on : Monday, May 28, 2018 - 5:01:02 PM
Last modification on : Thursday, April 11, 2019 - 4:02:23 PM

Identifiers

Citation

D. Peiffert, J.-M. Hannoun-Lévi, S. Oldrini, C. Brunaud. Arrêt de la commercialisation des fils d’iridium 192 en France : proposition du groupe de curiethérapie de la Société française de radiothérapie oncologique. Cancer Radiothérapie, Elsevier Masson, 2014, 18 (5-6), pp.441 - 446. ⟨10.1016/j.canrad.2014.08.001⟩. ⟨hal-01801809⟩

Share

Metrics

Record views

48